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LETTERS TO THE EDITOR
Comparison of Troponin T and
Creatine Kinase-MB Fraction in
Evaluating Cardiac Patients Postoperatively
Dr. Januzzi and colleagues in a recent study (1) published in the
Journal suggest replacement of creatine kinase-MB fraction (CK-
MB) with serum troponin testing for postoperative evaluation of
the cardiac surgical patient. An important point to remember is the
release pattern of these markers. Although the rise (CK-MB 4 to
8 h; CK-MB isoform 2 to 6 h; cardiac troponin I [cTnI] 4 to 6 h;
cardiac troponin T [cTnT] 4 to 8 h) and peak (CK-MB 12 to 24 h;
CK-MB isoform 18 h; cTnI 12 h; cTnT 12 to 28 h) are similar, the
markers differ greatly in their return to normal (CK-MB 72 to 96 h;
CK-MB isoform 24 h; cTnI 3 to 10 days; cTnT 7 to 10 days) (2).
Because of their prolonged elevation in the blood (up to 10
days), cardiac troponins may reflect a summation of preoperative,
perioperative, and postoperative events, thereby limiting the ability
to detect perioperative injury exclusively. In contrast, CK-MB and
its isoforms have a more rapid clearance and return to normal more
quickly, thus facilitating better timing of myocardial injury (3).
The long circulating half-lives of the cardiac troponins make it
difficult to distinguish new episodes of myocardial necrosis from
earlier episodes (4,5). Hence, reinfarctions may be difficult to
diagnose with the sole use of cardiac troponin assays, if the initial
myocardial infarction (MI) occurred within a week of cardiac
surgery. Subsequently, both CK-MB and cardiac troponins are
concurrently useful and not mutually exclusive in the diagnosis of
postoperative MI and reinfarction after coronary artery bypass graft
surgery.
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REPLY
We appreciate the comments of Drs. Chen-Scarabelli and Scara-
belli. We agree that the distinctly different release kinetics of
creatine kinase-MB (CK-MB) and troponin T (TnT) allow for
complementary information in certain settings, particularly that of
reinfarction. Indeed, it has been suggested that CK-MB be consid-
ered the marker of choice for the detection of reinfarction (1).
Though it was not the purpose of our study (2) to compare the
prognostic role of cardiac markers among patients undergoing
cardiac surgery soon after acute cardiac myonecrosis, among our
cohort of 224 patients, 58 had TnT data available preoperatively.
Of these, 26 had a level0.10 ng/ml (at the time the conventional
upper limit of normal for myocardial infarction [MI]). No clear
association between elevated preoperative TnT and adverse post-
operative outcomes was noted, nor did the elevation of preopera-
tive TnT obscure the markedly powerful prognostic ramifications
of marked elevations of TnT in the postoperative setting, which
were independently prognostic, irrespective of preoperative TnT
levels. This may be because the magnitude of TnT release
identifying patients at risk for impending postoperative complica-
tions was so significant at each time point (with mean levels among
complicated patients reaching nearly 9 ng/ml), compared to the
generally lower levels of TnT released in the setting of most acute
coronary syndromes. Given the small number of patients with
elevated preoperative TnT in our study, however, it is impossible
to characterize conclusively the comparative value of cardiac
markers in this situation.
We agree that for the unusual circumstance of urgent cardiac
surgery in the setting of a recent large acute MI, a cardiac marker
with shorter serum existence such as CK-MB might be preferable
for postoperative biochemical risk stratification. Finally, as we and
others have demonstrated, the “expected” magnitude of TnT
release following cardiac surgery varies between different proce-
dures, and not all patients undergoing cardiac surgical procedures
are expected to release large amounts of TnT (2–4). An example
of this would be coronary artery bypass grafting without cardio-
pulmonary bypass, which is associated with significantly lower
amounts of postoperative TnT release (3,4). In such patients,
significant elevations of preoperative TnT might obviate the use of
this marker for postoperative risk stratification. Nonetheless, for
many, if not most patients undergoing cardiac surgical procedures,
we believe that postoperative measurement of cardiac TnT affords
superior prognostic information.
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